ABUS R&D to Revenue
Arbutus Biopharma Corp · R&D to Revenue
ABUS R&D to Revenue
Latest reported285.80%period ending
ABUS Quarterly R&D/Revenue (33.96% → 285.80%)
Latest values, visible window
High-resolution chart · PNG
ABUS r&d to revenue history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 285.7988% | |
| 2.3001% | |
| 476.3083% | |
| 1,092.2495% | |
| 51.1966% | |
| 507.8798% | |
| 559.7205% | |
| 1,065.9447% | |
| 900.9849% | |
| 1,005.4178% | |
| 818.8345% | |
| 432.997% | |
| 380.3913% | |
| 273.2915% | |
| 367.478% | |
| 336.9456% | |
| 161.0982% | |
| 146.7451% | |
| 599.2514% | |
| 500.2695% | |
| 678.3598% | |
| 652.248% | |
| 687.0075% | |
| 792.1865% | |
| 691.2153% | |
| 698.5915% | |
| 3,476.7614% | |
| 579.2551% | |
| 1,950.9954% | |
| 2,166.7158% | |
| 659.2968% | |
| 1,043.8563% | |
| 1,314.791% | |
| 971.3788% | |
| 703.3149% | |
| 225.4353% | |
| 1,486.5255% | |
| 5,902.9787% | |
| -8,797.9487% | |
| 2,033.3333% | |
| 4,923.9482% | |
| 2,179.7678% | |
| 117.4838% | |
| 402.3124% | |
| 285.2941% | |
| 225.4806% | |
| 273.6092% | |
| 213.4113% | |
| 513.418% | |
| 185.1919% | |
| 92.7783% | |
| 185.8458% | |
| 172.7912% | |
| 190.8095% | |
| 476,374,372.9194% | |
| 101.6875% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 332,527,197.7793% | |
| 50.3131% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 129.1856% | |
| 224.7596% | |
| 0% | |
| 71.2984% | |
| 55.4559% | |
| 33.9605% |